ABL1 and anemia: The patient had received imatinib 400 mg daily in the first 8 years after CML diagnosis, with deep molecular remission (BCR::ABL/ABL 0.5% International Scale MR4, MR4,5), which had to be discontinued due to recurrent episodes of hemorrhagic eyelid edema and moderate anemia associated with the drug.